Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.60 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.60 |
| ▸ | AQP1 | P29972 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | VCP | P55072 | 12/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636279 | 0.99 | NPY5R (0.61) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| SCHEMBL8892672 | 0.92 | NPY5R (0.56) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| SCHEMBL8890247 | 0.85 | NPY5R (0.61) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| SCHEMBL8889919 | 0.84 | VCP (0.52) | VCP | |
| Hydrochloric Acid SCHEMBL2675360 | 0.84 | NPY5R (0.62) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| Hydrochloric Acid SCHEMBL8906965 | 0.84 | NPY5R (0.62) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| SCHEMBL8898270 | 0.83 | VCP (0.54) | NPY5RSLC6A4VCP | |
| SCHEMBL8900652 | 0.83 | VCP (0.49) | NPY5RAQP1ALDH1A1ADRA2AMAPT | |
| SCHEMBL3947713 | 0.83 | ADRA2A (0.69) | NPY5RADRA2AMCHR1VCP | |
| SCHEMBL8891157 | 0.83 | NPY5R (0.54) | NPY5RVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20210315963-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS, LLC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3833373-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Diapin Therapeutics LLC (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112739365-A | Tripeptides and treatment of metabolic, cardiovascular and inflammatory disorders | 糖平制药公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020033919-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS, LLC (US) | 2020-02-13 | — | — | WO | disclosed |
| US-9029400-B2 | 5-oxoisoxazoles as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2102198-B1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8946212-B2 | Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2015-02-03 | — | — | US | disclosed |
| EP-1987042-B1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| US-8921404-B2 | Azole derivatives in the form of lipase and phospholipase inhibitors | SANOFI (FR) | 2014-12-30 | — | — | US | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6713265-B1 | MEASURING THE BINDING OF GTP GAMMA S TO CELLS EXPRESSING Y5 RECEPTOR IN THE PRESENCE AND IN THE ABSENCE OF COMPOUND OF INTEREST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-6645774-B1 | Administering for treatment of obesity, bulimia or anorexia | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20020103123-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6316203-B1 | MONITORING ACTIVITY OF NERVOUS SYSTEM LIGAND; INCUBATE LIGAND AND TRANSFECTED CELL, DETECT AMPLIFICATION IN BINDING PROTEIN ACTIVITY, AMPLIFICATION IN BINDING PROTEIN ACTIVITY INDICATES AGONIST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-5989920-A | RECEPTOR BINDING ASSAY FOR SCREENING DRUGS WHICH BIND TO HUMAN OR RAT Y5 RECEPTOR BY CONTACTING NONNEURONAL CELLS TRANSFECTED WITH VECTOR HAVING SEQUENCE CODING FOR RECEPTOR AND DETECTING BINDING; TREATMENT OF OBESITY, EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
| US-5968819-A | FOR MODIFYING FEEDING BEHAVIOR IN CONNECTION WITH EATING DISORDERS; FOR SCREENING ANTAGONISTS, AGONISTS; FOR PROBES TO DETECT RECEPTORS; ANTISENSE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103123-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | NPY5R, NPY4R, NPY1R | ADRA2A 1055/4885SLC6A4 353/4885NPY5R 1/4885 |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | ADRA2A 766/4885SLC6A4 2369/4885NPY5R 1106/4885 |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | UGP2, UGDH, UGT1A1 | ADRA2A 2062/4885SLC6A4 3718/4885NPY5R 2815/4885 |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | ADRA2A 1837/4885SLC6A4 4240/4885NPY5R 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.